Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Medicine | 3 | 2020 | 41 | 1.170 |
Why?
|
| Critical Care | 5 | 2020 | 416 | 1.120 |
Why?
|
| Noninvasive Ventilation | 1 | 2025 | 68 | 0.830 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 741 | 0.740 |
Why?
|
| Consensus | 2 | 2020 | 174 | 0.700 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2024 | 165 | 0.680 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 30 | 0.670 |
Why?
|
| Alanine | 1 | 2021 | 49 | 0.670 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2021 | 20 | 0.670 |
Why?
|
| Guideline Adherence | 1 | 2023 | 310 | 0.640 |
Why?
|
| Asthma | 1 | 2025 | 489 | 0.630 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 100 | 0.620 |
Why?
|
| Dexamethasone | 1 | 2021 | 214 | 0.610 |
Why?
|
| Societies, Medical | 3 | 2020 | 401 | 0.610 |
Why?
|
| Sepsis | 1 | 2023 | 309 | 0.570 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 301 | 0.550 |
Why?
|
| Lung | 1 | 2023 | 969 | 0.530 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 206 | 0.530 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.520 |
Why?
|
| Sleep | 1 | 2020 | 246 | 0.520 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 464 | 0.490 |
Why?
|
| Pandemics | 1 | 2020 | 692 | 0.460 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 50 | 0.410 |
Why?
|
| Pneumonia | 2 | 2011 | 295 | 0.310 |
Why?
|
| United States | 5 | 2023 | 8190 | 0.270 |
Why?
|
| Humans | 15 | 2025 | 65826 | 0.270 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 349 | 0.260 |
Why?
|
| Respiratory Physiological Phenomena | 2 | 2023 | 9 | 0.250 |
Why?
|
| Acute Disease | 2 | 2025 | 664 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 808 | 0.210 |
Why?
|
| Societies | 1 | 2023 | 24 | 0.190 |
Why?
|
| Nuclear Localization Signals | 1 | 2002 | 20 | 0.190 |
Why?
|
| Interleukin-16 | 1 | 2002 | 25 | 0.190 |
Why?
|
| Respiratory Function Tests | 1 | 2023 | 195 | 0.180 |
Why?
|
| Protein Precursors | 1 | 2002 | 85 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2004 | 155 | 0.180 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2021 | 5 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 809 | 0.170 |
Why?
|
| Immunization, Passive | 1 | 2021 | 97 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 72 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 162 | 0.160 |
Why?
|
| Disease Progression | 1 | 2025 | 1229 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2021 | 108 | 0.160 |
Why?
|
| Advisory Committees | 1 | 2020 | 111 | 0.150 |
Why?
|
| Hemodynamics | 1 | 2021 | 253 | 0.150 |
Why?
|
| Delphi Technique | 1 | 2019 | 113 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Patient Selection | 1 | 2021 | 484 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2021 | 332 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 757 | 0.120 |
Why?
|
| Child | 1 | 2023 | 4653 | 0.090 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2011 | 5 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2014 | 436 | 0.080 |
Why?
|
| Pneumococcal Vaccines | 1 | 2011 | 22 | 0.080 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 95 | 0.080 |
Why?
|
| Risk | 1 | 2011 | 375 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2011 | 100 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2011 | 213 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2011 | 553 | 0.060 |
Why?
|
| Amphetamines | 1 | 2004 | 5 | 0.050 |
Why?
|
| Bronchial Spasm | 1 | 2004 | 8 | 0.050 |
Why?
|
| Solvents | 1 | 2004 | 60 | 0.050 |
Why?
|
| Pulmonary Edema | 1 | 2004 | 29 | 0.050 |
Why?
|
| Narcotics | 1 | 2004 | 57 | 0.050 |
Why?
|
| Pneumothorax | 1 | 2004 | 49 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 161 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2004 | 107 | 0.050 |
Why?
|
| Pyridones | 1 | 2024 | 43 | 0.050 |
Why?
|
| Cannabis | 1 | 2004 | 54 | 0.050 |
Why?
|
| Cocaine | 1 | 2004 | 101 | 0.050 |
Why?
|
| Respiratory Tract Infections | 1 | 2004 | 90 | 0.050 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2002 | 11 | 0.050 |
Why?
|
| Casein Kinase II | 1 | 2002 | 16 | 0.050 |
Why?
|
| CDC2 Protein Kinase | 1 | 2002 | 38 | 0.050 |
Why?
|
| G1 Phase | 1 | 2002 | 58 | 0.050 |
Why?
|
| COS Cells | 1 | 2002 | 180 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2002 | 115 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 157 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 252 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2002 | 344 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 672 | 0.040 |
Why?
|
| Alcoholism | 1 | 2004 | 329 | 0.040 |
Why?
|
| Transfection | 1 | 2002 | 700 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2002 | 419 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2002 | 963 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 1589 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1980 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 51 | 0.030 |
Why?
|
| Animals | 1 | 2002 | 21489 | 0.010 |
Why?
|